Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.
The antimicrobial susceptibility profile of 419 clinical isolates of Pseudomonas aeruginosa obtained from intensive care unit patients was determined. Amikacin and piperacillin/tazobactam were the most active antimicrobials evaluated. Fifty isolates (11.9%) were resistant to antimicrobials from > or =3 classes. Ninety-six percent of multidrug-resistant (MDR) isolates remained fully susceptible to colistin (polymyxin E).